CDKN2A and primary central nervous system lymphoma: Epigenetic modifications that may also participate in PCNSL pathogenesis include hypermethylation of DAPK (84%), CDKN2A (75%), MGMT (52%), and RFC (30%), with prospective therapeutic value [25].